Cervical Cancer - Pipeline Review, H2 2020

November 2020 | 1768 pages | ID: CE54C688042EN
Global Markets Direct

Abstracts

Cervical Cancer - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2020, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 89, 88, 3, 49, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 2, 13 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cervical Cancer - Overview
Cervical Cancer - Therapeutics Development
Cervical Cancer - Therapeutics Assessment
Cervical Cancer - Companies Involved in Therapeutics Development
Cervical Cancer - Drug Profiles
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cervical Cancer - Pipeline by 3SBio Inc, H2 2020
Cervical Cancer - Pipeline by Aadi Bioscience Inc, H2 2020
Cervical Cancer - Pipeline by AbbVie Inc, H2 2020
Cervical Cancer - Pipeline by Abion Inc, H2 2020
Cervical Cancer - Pipeline by Abivax SA, H2 2020
Cervical Cancer - Pipeline by Advaxis Inc, H2 2020
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
Cervical Cancer - Pipeline by Adze Biotechnology Inc, H2 2020
Cervical Cancer - Pipeline by Affimed GmbH, H2 2020
Cervical Cancer - Pipeline by Agenus Inc, H2 2020
Cervical Cancer - Pipeline by Akeso Inc, H2 2020
Cervical Cancer - Pipeline by Almac Discovery Ltd, H2 2020
Cervical Cancer - Pipeline by Alphamab Oncology, H2 2020
Cervical Cancer - Pipeline by amcure GmbH, H2 2020
Cervical Cancer - Pipeline by Andes Biotechnologies, H2 2020
Cervical Cancer - Pipeline by Anew Oncology Inc, H2 2020
Cervical Cancer - Pipeline by Anteris Technologies Ltd, H2 2020
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2020
Cervical Cancer - Pipeline by Apimeds Inc, H2 2020
Cervical Cancer - Pipeline by Apollomics Inc, H2 2020
Cervical Cancer - Pipeline by Apotex Inc, H2 2020
Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2020
Cervical Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2020
Cervical Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2020
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2020
Cervical Cancer - Pipeline by Bayer AG, H2 2020
Cervical Cancer - Pipeline by BeiGene Ltd, H2 2020
Cervical Cancer - Pipeline by Beijing Neoantigen Biotechnology Co Ltd, H2 2020
Cervical Cancer - Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, H2 2020
Cervical Cancer - Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, H2 2020
Cervical Cancer - Pipeline by BioAtla LLC, H2 2020
Cervical Cancer - Pipeline by Biocad, H2 2020
Cervical Cancer - Pipeline by BIOCND Inc, H2 2020
Cervical Cancer - Pipeline by Biocon Ltd, H2 2020
Cervical Cancer - Pipeline by BioIntegrator Ltd, H2 2020
Cervical Cancer - Pipeline by Bioleaders Corp, H2 2020
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2020
Cervical Cancer - Pipeline by BioNTech SE, H2 2020
Cervical Cancer - Pipeline by Biotheus Inc, H2 2020
Cervical Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2020
Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2020
Cervical Cancer - Pipeline by Cellestia Biotech AG, H2 2020
Cervical Cancer - Pipeline by Cellid Co Ltd, H2 2020
Cervical Cancer - Pipeline by Centus Biotherapeutics Ltd, H2 2020
Cervical Cancer - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
Cervical Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
Cervical Cancer - Pipeline by Clovis Oncology Inc, H2 2020
Cervical Cancer - Pipeline by Convert Pharmaceuticals SA, H2 2020
Cervical Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2020
Cervical Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2020
Cervical Cancer - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020
Cervical Cancer - Pipeline by Cue Biopharma Inc, H2 2020
Cervical Cancer - Pipeline by Cytocom Inc, H2 2020
Cervical Cancer - Pipeline by CytomX Therapeutics Inc, H2 2020
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2020
Cervical Cancer - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2020
Cervical Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Cervical Cancer - Pipeline by Disulfican Ltd, H2 2020
Cervical Cancer - Dormant Projects, H2 2020
Cervical Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020